Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 10 | Vintage Vibes

Make America Healthy Again? Tobacco Executive Stephen Sayle Appointed to a Senior Leadership Role at the CDC

Stephen Sayle, a former tobacco executive, has been appointed as CDC deputy director for legislative affairs, sparking concerns about industry influence in public health policy.

International Business Times UK

Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Barchart

Trump Officially Flipped the Script on the War on Drugs, Issues Bold Orders on Marijuana and Psychedelics

Donald Trump has ordered fast-tracked research into psychedelics and moved to reschedule medical marijuana, signalling a sharp shift in Republican drug policy.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics

The agency issued "national priority vouchers" for the two drugs six days after President Donald Trump promised to facilitate approval of psychedelic therapies.

Reason

Trail mix sold at Meijer in six states under recall for allergy risk

Trail mix containing two of the nine ‘major allergens’ has been removed from stores across six states

The Independent UK

FDA expedites review of three psychedelic drugs after Trump order

IN FULL

The Independent UK

Three psychedelic drugs to undergo ‘ultra-fast’ FDA review after Trump order

The recent moves reflect growing support for the mind-altering substances among Trump’s supporters

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Trump psychedelics order largely symbolic, analysts say

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push

The Guardian - US

'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness

A gene therapy made by Regeneron is the first treatment of its kind approved for genetic hearing loss.

LiveScience

Marijuana Rescheduled

Plus: skyway socialism, reconsider the lobster, D.C.'s urban growth, and more...

Reason

‘Can I have some, please?’: has Trump opened the door to a psychedelic future?

Order to speed hallucinogen research hailed as ‘threshold moment’ but concerns remain over access and protections

The Guardian - US

RFK Jr.'s peptide push could become next wellness boom

The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs.

Axios

Remote Patient Monitoring vs Chronic Care Management vs RTM: What’s the Difference?

The healthcare industry is rapidly evolving, and digital health solutions are at the forefront of this transformation.

inkl

Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind

A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.

LiveScience

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

Trump's Embrace of Psychedelic Therapy Leaves Most Users on the Wrong Side of the Law

The medical model assumes that people should be allowed to use psychedelics only for government-approved reasons.

The Independent UK

Cantaloupe recall upgraded in US over potentially deadly contamination concerns

Recalled fruit was distributed to retailers in four states

Reason

The COVID Reckoning Doesn't Go Far Enough

Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.

Barchart

Jazz Pharmaceuticals Stock, a Barchart Favorite, Trends Higher as Trump Renews Cannabis Hopes. Should You Buy JAZZ Here?

Jazz Pharmaceuticals stock pops as President Trump signals renewed urgency to reclassify cannabis as Schedule III drug. Technicals signal further upside ahead in JAZZ shares.

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

The Promise and Limits of Trump's Psychedelic Therapy Order

The president's facilitation of research and FDA review could help make psychedelics available to approved patients. But what about everyone else?

MarketBeat

This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

Barchart

Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

Reason

Trump Signs Psychedelics Order

Plus: ship seizures, the best free bread in America, and more...

We Got This Covered

‘Do you want FDA approval?’: Trump wins over Joe Rogan by green-lighting a drug research idea he had from a podcast

Here is the most random way to get policy greenlit.

Axios

How Trump is wooing Joe Rogan after their split

The president knows that keeping Rogan close still matters.

International Business Times UK

Trump Signs Executive Order Endorsing Psychedelic Psilocybin and Ibogaine; Asks 'Can I Have Some, Please?'

President Trump signed an executive order to expedite the review and funding of psychedelic drugs such as psilocybin and ibogaine to treat serious mental illnesses and address public health crises.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

346 stories

Raymond James

270 stories

the Food and Drug Administration

214 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.